- Home
- MRNA vs UTHR Comparison
MRNA vs UTHR Comparison
Compare MRNA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- UTHR
- Stock Information
- Founded
- MRNA 2010
- UTHR 1996
- Country
- MRNA United States
- UTHR United States
- Employees
- MRNA N/A
- UTHR N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- MRNA Health Care
- UTHR Health Care
- Exchange
- MRNA Nasdaq
- UTHR Nasdaq
- Market Cap
- MRNA 13.4B
- UTHR 13.8B
- IPO Year
- MRNA 2018
- UTHR 1999
- Fundamental
- Price
- MRNA $28.02
- UTHR $313.13
- Analyst Decision
- MRNA Hold
- UTHR Buy
- Analyst Count
- MRNA 20
- UTHR 13
- Target Price
- MRNA $46.24
- UTHR $382.00
- AVG Volume (30 Days)
- MRNA 8.6M
- UTHR 691.8K
- Earning Date
- MRNA 08-01-2025
- UTHR 07-30-2025
- Dividend Yield
- MRNA N/A
- UTHR N/A
- EPS Growth
- MRNA N/A
- UTHR 17.94
- EPS
- MRNA N/A
- UTHR 25.63
- Revenue
- MRNA $3,078,000,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- MRNA N/A
- UTHR $14.37
- Revenue Next Year
- MRNA $10.04
- UTHR $6.59
- P/E Ratio
- MRNA N/A
- UTHR $12.22
- Revenue Growth
- MRNA N/A
- UTHR 17.62
- 52 Week Low
- MRNA $23.15
- UTHR $266.98
- 52 Week High
- MRNA $91.99
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- MRNA 46.33
- UTHR 61.16
- Support Level
- MRNA $25.30
- UTHR $292.34
- Resistance Level
- MRNA $27.08
- UTHR $306.00
- Average True Range (ATR)
- MRNA 1.33
- UTHR 9.55
- MACD
- MRNA -0.31
- UTHR 1.92
- Stochastic Oscillator
- MRNA 32.38
- UTHR 97.36
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.